The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Novel immune therapies in the future of myeloma treatment – a hot topic at COMy 2022
There are several immune therapies, including CAR-T cells and bispecific antibodies, that have changed the treatment landscape of multiple myeloma over the last few years and are constantly evolving. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the importance of better understanding these immune therapies and issues including toxicity management, which will all be discussed by experts at the COMy 2022 congress in Paris, France.
